Myota, a health technology company developing prebiotic fiber blends backed by clinical research, has raised $4.5M in a Series A round led by PeakBridge.
The funding will support growth of Myota’s B2B sales operations in the US and Europe, expand its direct-to-consumer business, and fund further clinical research on its ingredients.
Addressing The Market Opportunity
Fiber is one of the most widely recognized pillars of human health, yet the majority of fiber-based products on the market have been built around commodity ingredients without clinical validation. For food and beverage companies looking to make substantiated health claims, this gap between what is available and what is defensible has created a meaningful opportunity.
Myota has positioned itself at that intersection, developing fiber blends that are both patented and validated through randomized controlled trials, giving its B2B customers ingredients they can put into products with claims that hold up to scientific scrutiny.
Advertisement
How The Technology Works
Myota’s platform measures how an individual’s gut bacteria ferment different types of fiber and uses that data to build blends that produce short-chain fatty acids reliably across varied microbiomes. The company’s patented prebiotic fiber blends are designed to improve gut health while minimizing digestive discomfort, and are formulated to be added to everyday food and drink products.
Clinical studies on Myota’s ingredients have shown improvements in insulin sensitivity, blood sugar control, inflammation, and mood, including reductions in stress and anxiety. These outcomes form the evidence base that the company uses to differentiate its ingredients from those built primarily on marketing positioning.
Growth And Market Traction
Founded by Dr Thomas Gurry, Myota has developed both a B2B ingredient business serving food and beverage, food service, and wellness companies, and a direct-to-consumer channel. PeakBridge backed the company at an early stage and has continued its support through the Series A, citing the strength of Myota’s scientific foundation and clinical trial results as the basis for its conviction in the category.
Expansion Plans
The Series A funding will be used to scale B2B sales operations across the US and Europe, grow the direct-to-consumer business, and continue building the clinical evidence base behind Myota’s ingredients. The company is focused on meeting rising demand from food and wellness companies seeking fiber ingredients with claimable, clinically supported benefits.
Looking Ahead
Kat Stennett, co-founder and CEO of Myota, described what the company has built and why the market is ready for it: “Fiber is one of the most powerful and overlooked levers for human health, and for years the products on shelves haven’t done it justice. What’s been missing is fiber that works across real, varied microbiomes and stands up to clinical scrutiny. That is what we’ve built, and it’s why companies across F&B, food service, and wellness are coming to us to put genuine, claimable benefits into their products. This round lets us meet that demand at scale.”
Thomas Gurry, co-founder and Chief Scientific Officer, explained the scientific differentiation behind the platform: “We can measure how an individual’s gut bacteria ferment different fibers, and we use that to build blends that produce short-chain fatty acids reliably across very different microbiomes. Our randomized controlled trials have shown improvements in insulin sensitivity, blood sugar control, inflammation and mood including stress and anxiety. That evidence base is what separates a functional ingredient from a marketing claim.”
Yoni Glickman, Managing Partner at PeakBridge, outlined the firm’s perspective on the investment: “Most gut-health products are a marketing story built on one or two commodity fibers. Myota built and patented the science first and then validated the outcomes in clinical trials. We saw fiber becoming a pillar of modern nutrition five years ago, backed Myota early, and we’re proud to continue supporting their excellent team now.”
About Myota
Myota is a health technology company that develops patented prebiotic fiber blends and a digital health platform to support gut health and broader metabolic wellbeing. The company uses microbiome research and clinical data to create ingredients that produce short-chain fatty acids reliably across diverse microbiomes. Myota serves food and beverage, food service, and wellness companies through its B2B ingredient business, alongside a direct-to-consumer channel.
